AR and prostate carcinoma: In line with the above molecular insights, treatment with CBPD-409 resulted in stronger cytotoxicity (IC50 ranging between 2 nM to 11 nM) in all tested AR-positive prostate cancer cell lines relative to GNE-049 (IC50 ranging between 650 nM to 1900 nM; Figures 6A and S7A–B).